$AMRN - On our trading list. Plunging after hours as it appears the company lost a patent infringement case. This is part of why the biotech space is a high-beta gamble at times. Sell-off comes as this was unexpected result for many. This huge drop after hours maybe a buying opportunity (or not). We will need to see more details on what this means for their fish oil drug. Also this is a great example of why some pro traders have puts or some kind of hedge in case of bad results. The decision, will most likely be appealed by Amarin. It is a victory for two drug makers, Hikma Pharmaceuticals and Dr. Reddy’s Laboratories, who are seeking to make and sell generic versions of Vascepa. Amarin shares were down 65% to $4.75 in after-hours trading. Most analysts who had been following the Vascepa patent litigation trial since it started in January had been predicting a ruling in Amarin’s favor. The judge overseeing the case decided otherwise. While the generic versions of Vascepa would infringe on claims included in Amarin’s patents, those claims were “obvious” and therefore invalid, the ruling stated. Amarin has not commented yet. Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page